A Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral Ganciclovir

NCT00000668 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

NIH

Sponsor class

Conditions

Cytomegalovirus Retinitis
HIV Infections

Interventions

DRUG: Ganciclovir

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]